Literature DB >> 12654609

Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease.

Don D Sin1, S F Paul Man.   

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) increases the risk of cardiovascular disease 2- to 3-fold. The factors responsible for this association remain largely unknown. METHODS AND
RESULTS: We analyzed data from participants, > or =50 years of age, of the Third National Health and Nutrition Examination Survey (n=6629) to determine whether C-reactive protein (CRP) and other systemic inflammatory markers are present in participants with chronic airflow obstruction and are associated with cardiac injury. Participants with severe airflow obstruction had circulating leukocyte, platelet, and fibrinogen levels that were 460/ microL (95% confidence interval [CI], 30 to 890/ microL), 39 510/ microL (95% CI, 21 730 to 57 290/ microL), and 41.63 mg/dL (95% CI, 19.87 to 63.39 mg/dL) higher, respectively, than in those without airflow obstruction. They were also 2.18 times (95% CI, 1.46 to 3.27) more likely to have an elevated circulating CRP level. Moderate airflow obstruction was associated with smaller but still significant increases in these levels. Moderate and severe airflow obstruction was associated with increased occurrence of ischemic changes on electrocardiograms of participants. In the presence of both highly elevated CRP and moderate or severe airflow obstruction, the Cardiac Infarction Injury Score was 2.68 and 5.88 U higher, respectively, than in those without airflow obstruction and with low CRP, which suggests an additive effect of CRP and COPD on the risk of cardiac injury.
CONCLUSION: Low-grade systemic inflammation was present in participants with moderate to severe airflow obstruction and was associated with increased risk of cardiac injury. This may in part explain the high rates of cardiovascular complications in COPD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12654609     DOI: 10.1161/01.cir.0000056767.69054.b3

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  277 in total

Review 1.  The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies.

Authors:  Magali Poulain; Mariève Doucet; Geneviève C Major; Vicky Drapeau; Frédéric Sériès; Louis-Philippe Boulet; Angelo Tremblay; François Maltais
Journal:  CMAJ       Date:  2006-04-25       Impact factor: 8.262

2.  C-reactive protein levels are raised in stable Chronic obstructive pulmonary disease patients independent of smoking behavior and biomass exposure.

Authors:  Funda Aksu; Nermin Capan; Kurtuluş Aksu; Ruhsar Ofluoğlu; Sema Canbakan; Bünyamin Yavuz; Kadir Okhan Akin
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

3.  Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

Authors:  Nathaniel M Hawkins; Zhen Huang; Karen S Pieper; Scott D Solomon; Lars Kober; Eric J Velazquez; Karl Swedberg; Marc A Pfeffer; John J V McMurray; Aldo P Maggioni
Journal:  Eur J Heart Fail       Date:  2009-01-27       Impact factor: 15.534

Review 4.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

Review 5.  Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit?

Authors:  S F Paul Man; Don D Sin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Should mild COPD be treated? Evidence for early pharmacological intervention.

Authors:  Amany F Elbehairy; Katherine A Webb; J Alberto Neder; J Alberto Neder; Denis E O'Donnell
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

7.  Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function.

Authors:  S Vamsee Raju; Patricia L Jackson; Clifford A Courville; Carmel M McNicholas; Peter A Sloane; Gina Sabbatini; Sherry Tidwell; Li Ping Tang; Bo Liu; James A Fortenberry; Caleb W Jones; Jeremy A Boydston; J P Clancy; Larry E Bowen; Frank J Accurso; J Edwin Blalock; Mark T Dransfield; Steven M Rowe
Journal:  Am J Respir Crit Care Med       Date:  2013-12-01       Impact factor: 21.405

8.  Abdominal Visceral Adipose Tissue is Associated with Myocardial Infarction in Patients with COPD.

Authors:  Alejandro A Diaz; Tom P Young; Sila Kurugol; Erick Eckbo; Nina Muralidhar; Joshua K Chapman; Gregory L Kinney; James C Ross; Raul San Jose Estepar; Rola Harmouche; Jennifer L Black-Shinn; Matthew Budoff; Russell P Bowler; John Hokanson; George R Washko
Journal:  Chronic Obstr Pulm Dis       Date:  2015

9.  Airflow obstruction, atherosclerosis and cardiovascular risk factors in the AGES Reykjavik study.

Authors:  Gunnar Gudmundsson; Olof Birna Margretardottir; Martin Ingi Sigurdsson; Tamara B Harris; Lenore J Launer; Sigurdur Sigurdsson; Orn Olafsson; Thor Aspelund; Vilmundur Gudnason
Journal:  Atherosclerosis       Date:  2016-07-28       Impact factor: 5.162

Review 10.  Cardiac disease in chronic obstructive pulmonary disease.

Authors:  Jeremy A Falk; Steven Kadiev; Gerard J Criner; Steven M Scharf; Omar A Minai; Philip Diaz
Journal:  Proc Am Thorac Soc       Date:  2008-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.